Latest news with #EliLilly
Yahoo
3 hours ago
- Business
- Yahoo
Lilly set for strong quarter after Novo profit warning
By Patrick Wingrove and Bhanvi Satija (Reuters) -Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival Novo Nordisk did on Tuesday, and are anxiously awaiting a full-year outlook and updates on an experimental obesity drug to gauge the U.S. drugmaker's longer-term health. Lilly's weight-loss drug Zepbound leads the U.S. market and has faced less competition from cheaper copies made by compounding pharmacies, giving it an edge, they said, after investors wiped $70 billion from Novo's market value. Novo, which sells the obesity drug Wegovy and related diabetes medicine Ozempic, on Tuesday issued a profit warning, citing lower U.S. growth expectations and competition including from compounded versions. "I think that this is a pretty positive report for Lilly just because it shows the competitive note it has against their largest competitor," said Dave Wagner, portfolio manager at Aptus Capital Advisors. Analysts expect Lilly to post second-quarter earnings of $5.57 per share on revenue of $14.71 billion, according to LSEG data. They are also looking for a full-year profit of $21.83 per share. Lilly has forecast adjusted earnings of $20.78 to $22.28 per share for 2025. Still, Lilly's shares fell nearly 5% on Tuesday, reflecting concern that the company could be vulnerable if Novo cuts prices aggressively or if its growth in the obesity market also slows more than expected, analysts and investors said. Zepbound holds just under 60% of the obesity market, while Lilly's diabetes drug Mounjaro - containing the same active ingredient - accounts for over half of its segment against Ozempic, according to IQVIA data shared with Reuters by an analyst. IQVIA did not immediately respond to a request for confirmation. UBS analyst Trung Huynh said data also showed Lilly was getting around two-thirds of new patients onto Zepbound. The company in December posted results from a large head-to-head trial showing patients on Zepbound lost an average of 20.2% of their weight after 72 weeks compared to 13.7% for the group treated with Wegovy. Lilly is also expected to be first to the market with the next generation of oral obesity drugs. Lilly has said it intends to seek approval for its experimental drug orforglipron by the end of the year. Lilly has felt less heat from compounded versions of its medicines than Novo Nordisk, Huynh said, largely because Wegovy and Ozempic both hit the market before Lilly's drugs and built up patient recognition sooner. Compounding pharmacies earlier this year were restricted under U.S. law from making drugs that were essentially copies of Wegovy and Zepbound, but can still make personalized doses for patients who need them, or formulations not offered by FDA-approved medicines. Investors earlier this year were rattled by CVS Health's decision to drop Zepbound from some lists of medicines it covers for reimbursement starting on July 1, triggering a 10% share price plunge. But Lilly's stock has declined marginally so far this year, compared to a more than 40% fall in Novo Nordisk's shares, including Tuesday's moves. Barclays analyst Emily Field said Lilly could calm investors next week by reaffirming or boosting revenue and profit outlooks, or simply by delivering strong financial results. Brian Mulberry at Zacks Investment Management said signs of softness in the obesity or diabetes drug market, especially from a peer like Novo, typically trigger broad-based selling, which might account for Lilly's share drop on Tuesday. Sign in to access your portfolio
Time of India
6 hours ago
- Health
- Time of India
Obesity drugs gain weight in labs: Several clinical trials by big and small pharma cos underway
Driven by the success of Wegovy and Mounjaro, numerous pharma companies are developing anti-obesity drugs, with over 170 in various stages. While giants like Novartis and GSK are cautious, Eli Lilly and Novo Nordisk lead the race. Research expands beyond GLP-1 targets, exploring oral options and addressing conditions like MASH and CVD. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: As blockbuster weight-loss drugs Wegovy (semaglutide) and Mounjaro (tirzepatide) reap billions of dollars on hysteric demand for innovators Novo Nordisk and Eli Lilly , more pharma companies — big and small — are racing to join the many as 170 new anti- obesity drugs are in various stages of development — from preclinical evaluation to advanced trials — though medical experts advise caution against their harmful effects due to reckless self-medication. Data collated from the obesity drugs tracker of Stat News, a popular Boston-based website on medical and healthcare analytical and investigative news, show Amgen, AstraZeneca , Boehringer Ingelheim, Roche and Regeneron are among the big names that are part of the choking giants like Swiss drug maker Novartis and UK-based GSK are taking a cautious view of the opportunity. Pfizer had a setback recently with its experimental pill danuglipron that resulted in liver injury in a patient during the clinical trials. Eli Lilly, which is seeing record-shattering sales, with its Zepbound/Mounjaro brands, has at least nine drugs listed in active Danish rival Novo Nordisk is working on 14 leads, including additional studies on the already approved a mailed response to ET, an Eli Lilly India spokesperson said the company invests approximately 25% of its revenue in R&D, significantly exceeding industry benchmarks. 'We are strategically focusing on areas of high unmet need, such as obesity, a chronic disease that requires more effective treatment options. Our goal is to modernise how this disease is approached, and we are making bold, science-driven decisions to explore new treatment modalities,' she to orforglipron, its nonpeptide, oral GLP-1 receptor agonist being studied for the treatment of obesity and type-2 diabetes, the Lilly spokesperson said, 'We've seen so far, we have a high degree of confidence on what this molecule could mean for patients.' But several drugs on the Stat News tracker are once-a-week injectables with the sole exception of San Diego-based Skye Bioscience, which is developing a once a-month injectable drug. Interestingly, like orforglipron, at least 64 drugs being developed are in the oral or pill form, marking a shift that will make dosing compliance easier and result in lower manufacturing costs than the injectables.A growing number of Chinese companies including Innovent, Sciwind, Zhejiang Doer, Innogen and Jiangsu Hengrui are catching up with their western counterparts on the back of speedy trials and conducive regulatory pathways, while India's Sun Pharma is the only one from the country that is listed to develop its own molecule utreglutide in earlystages of clinical other big names from India such as Dr Reddy's, Biocon Cipla and Torrent are developing copies of semaglutide, which is pending patent expiry early next and obesity expert Rajiv Kovil told ET that the emergence of powerful anti-obesity therapies is driving a fundamental shift in the treatment of non-communicable diseases (NCDs). Now, he says, obesity care is no longer an afterthought, it's becoming the frontline strategy against News data show the areas of research for obesity drugs is rapidly expanding beyond targeting the GLP-1 gut hormones. Currently multiple modalities are being approached like silencing certain genes using the RNA interference technology that may have a longer effect than the injectables. Another biologic pathway is to target amylin, a hormone secreted by pancreas and has a role in stomach emptying and reduced calorie intake, without causing nausea or muscle of the research involves combining multiple targets like GLP-1/GIP and amylin competitive landscape is expected to change as at least 10 drugs are in phase-III clinical trials, the stage before which regulatory agencies grant marketing approvals. Besides the benefits in weight loss , the new experiments on an array of conditions are underway. Those include MASH (metabolic dysfunction-associated steatohepatitis), cardiovascular disease (CVD), obstructive sleep apnea, neurological disorders like Alzheimer's disease, polycystic ovary syndrome (PCOS), chronic kidney disease (CKD), heart failures and arthritis.
Economic Times
6 hours ago
- Health
- Economic Times
Obesity drugs gain weight in labs: Several clinical trials by big and small pharma cos underway
Mumbai: As blockbuster weight-loss drugs Wegovy (semaglutide) and Mounjaro (tirzepatide) reap billions of dollars on hysteric demand for innovators Novo Nordisk and Eli Lilly, more pharma companies — big and small — are racing to join the frenzy. As many as 170 new anti-obesity drugs are in various stages of development — from preclinical evaluation to advanced trials — though medical experts advise caution against their harmful effects due to reckless self-medication. Data collated from the obesity drugs tracker of Stat News, a popular Boston-based website on medical and healthcare analytical and investigative news, show Amgen, AstraZeneca, Boehringer Ingelheim, Roche and Regeneron are among the big names that are part of the choking pipeline. However, giants like Swiss drug maker Novartis and UK-based GSK are taking a cautious view of the opportunity. Pfizer had a setback recently with its experimental pill danuglipron that resulted in liver injury in a patient during the clinical trials. Eli Lilly, which is seeing record-shattering sales, with its Zepbound/Mounjaro brands, has at least nine drugs listed in active research. Its Danish rival Novo Nordisk is working on 14 leads, including additional studies on the already approved products. In a mailed response to ET, an Eli Lilly India spokesperson said the company invests approximately 25% of its revenue in R&D, significantly exceeding industry benchmarks. 'We are strategically focusing on areas of high unmet need, such as obesity, a chronic disease that requires more effective treatment options. Our goal is to modernise how this disease is approached, and we are making bold, science-driven decisions to explore new treatment modalities,' she said. Referring to orforglipron, its nonpeptide, oral GLP-1 receptor agonist being studied for the treatment of obesity and type-2 diabetes, the Lilly spokesperson said, 'We've seen so far, we have a high degree of confidence on what this molecule could mean for patients.' But several drugs on the Stat News tracker are once-a-week injectables with the sole exception of San Diego-based Skye Bioscience, which is developing a once a-month injectable drug. Interestingly, like orforglipron, at least 64 drugs being developed are in the oral or pill form, marking a shift that will make dosing compliance easier and result in lower manufacturing costs than the injectables. A growing number of Chinese companies including Innovent, Sciwind, Zhejiang Doer, Innogen and Jiangsu Hengrui are catching up with their western counterparts on the back of speedy trials and conducive regulatory pathways, while India's Sun Pharma is the only one from the country that is listed to develop its own molecule utreglutide in earlystages of clinical trials. The other big names from India such as Dr Reddy's, Biocon, Cipla and Torrent are developing copies of semaglutide, which is pending patent expiry early next year. FRONTLINE STRATEGY AGAINST NCDS Diabetologist and obesity expert Rajiv Kovil told ET that the emergence of powerful anti-obesity therapies is driving a fundamental shift in the treatment of non-communicable diseases (NCDs). Now, he says, obesity care is no longer an afterthought, it's becoming the frontline strategy against NCDs. Stat News data show the areas of research for obesity drugs is rapidly expanding beyond targeting the GLP-1 gut hormones. Currently multiple modalities are being approached like silencing certain genes using the RNA interference technology that may have a longer effect than the injectables. Another biologic pathway is to target amylin, a hormone secreted by pancreas and has a role in stomach emptying and reduced calorie intake, without causing nausea or muscle loss. Some of the research involves combining multiple targets like GLP-1/GIP and amylin analogues. The competitive landscape is expected to change as at least 10 drugs are in phase-III clinical trials, the stage before which regulatory agencies grant marketing approvals. Besides the benefits in weight loss, the new experiments on an array of conditions are underway. Those include MASH (metabolic dysfunction-associated steatohepatitis), cardiovascular disease (CVD), obstructive sleep apnea, neurological disorders like Alzheimer's disease, polycystic ovary syndrome (PCOS), chronic kidney disease (CKD), heart failures and arthritis.
Bloomberg
13 hours ago
- Business
- Bloomberg
Novo CEO's First Test Is Winning Back the US Weight-Loss Market
Novo Nordisk A/S's best-sellers Ozempic and Wegovy transformed the firm into a global pharmaceutical giant. But four years after Wegovy's US launch, the Danish drugmaker's growth is slowing. About one million patients in the US are taking cheaper copycat options. To reverse this decline, Novo named a new chief executive this week to win them back – and prove the company can still compete with US rival Eli Lilly & Co. Novo's copycat problem wasn't supposed to last this long. It began when the company was unable to meet customer demand for its weight-loss drugs in the US, clearing the way for compounding pharmacies to step in. These pharmacies are allowed to make and sell cheaper copies of a medicine when brand-name drugs are in short supply, and their products don't go have to go through the same rigorous approval process. They lost this permission this year, when authorities ruled the shortage had ended, but Novo's hopes for a quick recovery were still dashed on Tuesday when the drugmaker slashed its sales and profit forecasts. Shares closed down 23%, the steepest one-day drop on record.
Yahoo
13 hours ago
- Business
- Yahoo
Eli Lilly and Company (LLY) Announces New Phase 3 Trial Results for Orforglipron
Eli Lilly and Company (NYSE:LLY) is one of the . On July 21, Eli Lilly and Company (NYSE:LLY) announced new Phase 3 trial results for Orforglipron, which is an oral drug for adults with type 2 diabetes. This comes as a breakthrough for the company as Orforglipron is the first non-injectable GLP-1 receptor agonist to show strong results in this type of trial. The results showed that at 40 weeks, all tested doses of Orforglipron significantly lowered A1C. Moreover, the two highest doses also led to meaningful and statistically significant weight loss. The safety profile of the drug was also consistent, as the most common side effects were mild-to-moderate stomach issues like diarrhea and nausea, mostly during dose increases. In addition, discontinuation due to side effects was similar to other drugs in this class. The company expects to share topline results from ACHIEVE-2 later this year. In this trial, Orforglipron will be compared with dapagliflozin. The company remains on track to submit Orforglipron for weight management to global regulatory agencies by the end of this year and for type 2 diabetes by 2026. Eli Lilly and Company (NYSE:LLY) is an international pharmaceutical company that focuses on treatments for diabetes, oncology, immunology, neuroscience, and cardiometabolic health. Advanced Micro Devices, Inc. (NASDAQ:LLY) is an international semiconductor company that designs and sells high-performance processors and graphics chips used in data centers. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
